Literature DB >> 221809

Increased glomerular filtration rate after converting-enzyme inhibition in essential hypertension.

N K Hollenberg, S L Swartz, D R Passan, G H Williams.   

Abstract

To test the influence of an inhibitor of angiotensin-converting enzyme, teprotide (SQ 20881), we administered it to seven patients with essential hypertension and normal renal function and nine with an unequivocal reduction in creatinine clearance, caused by bilateral renal-artery stenosis in two and by essential hypertension in seven. Despite the fall in blood pressure (112.7 +/- 4.5 to 100.3 +/- 3.9 mm Hg, mean +/- S.E.M., P less than 0.01), there were prompt increases in both creatinine clearance (95.9 +/- 10.5 to 109.9 +/- 9.5 ml per minute per 1.73 m2 of body-surface area, P less than 0.01) and sodium excretion (17.0 +/- 5.9 to 31.7 +/- 7.2 mumol per minute, P less than 0.01) in patients with essential hypertension. The increase in glomerular filtration rate was most striking, averaging 33 per cent (66.0 +/- 10.3 to 88.0 +/- 9.2 ml per minute per 1.73 m2, P less than 0.001) in patients in whom an initial reduction was evident and hypertension was more severe. These observations suggest that a functional element, perhaps involving angiotensin-mediated renal vasoconstriction, frequently has a role in the reduction in glomerular filtration rate that occurs in essential hypertension. This class of agent may improve renal excretory function as it controls hypertension.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 221809     DOI: 10.1056/NEJM197907053010103

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  25 in total

1.  Effects of acute and chronic cilazapril treatment in spontaneously hypertensive rats.

Authors:  W Fischli; F Hefti; J P Clozel
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

Review 2.  ACE inhibitors and the kidney. A risk-benefit assessment.

Authors:  G Navis; H J Faber; D de Zeeuw; P E de Jong
Journal:  Drug Saf       Date:  1996-09       Impact factor: 5.606

3.  Angiotensin converting enzyme inhibition: a new therapeutic modality.

Authors:  H Gavras; F Charocopos; H Brunner; I Gavras
Journal:  Bull N Y Acad Med       Date:  1981-05

Review 4.  Beta-blockers and renal function.

Authors:  R Wilkinson
Journal:  Drugs       Date:  1982-03       Impact factor: 9.546

5.  Long-term effect of captopril on kidney function in various forms of hypertension.

Authors:  W Vetter; M Wehling; E C Foerster; U Kuhlmann; H J Boerlin; P Greminger; H Vetter
Journal:  Klin Wochenschr       Date:  1984-08-01

6.  Oral converting enzyme inhibitor in malignant hypertension.

Authors:  W Griswold; R McNeal; D O'Connor; V Reznik; S Mendoza
Journal:  Arch Dis Child       Date:  1982-03       Impact factor: 3.791

Review 7.  Renal effects of antihypertensive drugs.

Authors:  W A Schlueter; D C Batlle
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

Review 8.  Acute and chronic effects of angiotensin converting enzyme inhibitors on the essential hypertensive kidney.

Authors:  G P Reams; J H Bauer
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

9.  Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521.

Authors:  J A Millar; F H Derkx; K McLean; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

10.  Systemic and renal haemodynamic effects of angiotensin converting enzyme inhibition by zabicipril in young and in old normal men.

Authors:  R Naeije; A Fiasse; E Carlier; M Opsomer; M Leeman
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.